164
Views
15
CrossRef citations to date
0
Altmetric
Original Research

COL11A1 Was Involved in Cell Proliferation, Apoptosis and Migration in Non-Small Cell Lung Cancer Cells

, , &

References

  • Roman M, Baraibar I, Lopez I, et al. KRAS oncogene in non-small cell lung cancer: clinical perspectives on the treatment of an old target. Mol Cancer. 2018;17:33. doi:10.1186/s12943-018-0789-x.
  • Sun Y, Huang YH, Huang FY, et al. 3'-epi-12beta-hydroxyfroside, a new cardenolide, induces cytoprotective autophagy via blocking the Hsp90/Akt/mTOR axis in lung cancer cells. Theranostics. 2018;8(7):2044–2060. doi:10.7150/thno.23304.
  • Toss MS, Miligy IM, Gorringe KL, et al. Collagen (XI) alpha-1 chain is an independent prognostic factor in breast ductal carcinoma in situ. Mod Pathol. 2019;32:1460–1472. doi:10.1038/s41379-019-0286-9.
  • Wu YH, Huang YF, Chen CC, et al. Akt inhibitor SC66 promotes cell sensitivity to cisplatin in chemoresistant ovarian cancer cells through inhibition of COL11A1 expression. Cell Death Dis. 2019;10(4):322. doi:10.1038/s41419-019--8.
  • Wu YH, Huang YF, Chang TH, et al. Activation of TWIST1 by COL11A1 promotes chemoresistance and inhibits apoptosis in ovarian cancer cells by modulating NF-kappaB-mediated IKKbeta expression. Int J Cancer. 2017;141(11):2305–2317. doi:10.1002/ijc.30932.
  • Zhang Q, Wang C, Cliby WA. Cancer-associated stroma significantly contributes to the mesenchymal subtype signature of serous ovarian cancer. Gynecol Oncol. 2019;152(2):368–374. doi:10.1016/j.ygyno.2018.11.014.
  • Freire J, Garcia-Berbel L, Garcia-Berbel P, et al. Collagen type XI alpha 1 expression in intraductal papillomas predicts malignant recurrence. Biomed Res Int. 2015;2015:1. doi:10.1155/2015/812027.
  • Li A, Li J, Lin J, et al. COL11A1 is overexpressed in gastric cancer tissues and regulates proliferation, migration and invasion of HGC-27 gastric cancer cells in vitro. Oncol Rep. 2017;37(1):333–340. doi:10.3892/or.2016.5276.
  • Qin D, Wang W, Lei H, et al. CDDO-Me reveals USP7 as a novel target in ovarian cancer cells. Oncotarget. 2016;7(47):77096–77109. doi:10.18632/oncotarget.12801.
  • Shen L, Yang M, Lin Q, et al. COL11A1 is overexpressed in recurrent non-small cell lung cancer and promotes cell proliferation, migration, invasion and drug resistance. Oncol Rep. 2016;36(2):877–885. doi:10.3892/or.2016.4869.
  • Wu YH, Chang TH, Huang YF, et al. COL11A1 promotes tumor progression and predicts poor clinical outcome in ovarian cancer. Oncogene. 2014;33(26):3432–3440. doi:10.1038/onc.2013.307.
  • Chong IW, Chang MY, Chang HC, et al. Great potential of a panel of multiple hMTH1, SPD, ITGA11 and COL11A1 markers for diagnosis of patients with non-small cell lung cancer. Oncol Rep. 2006;16:981–988. doi:10.3892/or.16.5.981.
  • Fischer H, Stenling R, Rubio C, et al. Colorectal carcinogenesis is associated with stromal expression of COL11A1 and COL5A2. Carcinogenesis. 2001;22(6):875–878. doi:10.1093/carcin/22.6.875.
  • Rada M, Nallanthighal S, Cha J, et al. Inhibitor of apoptosis proteins (IAPs) mediate collagen type XI alpha 1-driven cisplatin resistance in ovarian cancer. Oncogene. 2018;37(35):4809–4820. doi:10.1038/s41388-018-0297-x.
  • Davies M. New modalities of cancer treatment for NSCLC: focus on immunotherapy. Cancer Manag Res. 2014;6:63–75. doi:10.2147/CMAR.S57550.
  • Mirzaei HR, Mirzaei H, Lee SY, et al. Prospects for chimeric antigen receptor (CAR) gammadelta T cells: a potential game changer for adoptive T cell cancer immunotherapy. Cancer Lett. 2016;380(2):413–423. doi:10.1016/j.canlet.2016.07.001.
  • Mirzaei HR, Rodriguez A, Shepphird J, et al. Chimeric antigen receptors T cell therapy in solid tumor: challenges and clinical applications. Front Immunol. 2017;8:1850.
  • Thomas A, Hassan R. Immunotherapies for non-small-cell lung cancer and mesothelioma. Lancet Oncol. 2012;13(7):e301–e310. doi:10.1016/S-2045(12)70126-2.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.